Contrast induced nephropathy management and prevention

Reading File

Finding Sources

Searching PubMed

"contrast induced nephropathy" prevention management

Reading File

I now have all the key content needed. Let me compile the comprehensive answer.

Contrast-Induced Nephropathy (CIN) / Post-Contrast Acute Kidney Injury (PC-AKI)

Terminology Clarification

Modern guidelines distinguish two related but distinct entities:

PC-AKI (Post-Contrast AKI): Any deterioration in renal function within 48 hours of intravascular iodinated contrast, regardless of cause - a correlative diagnosis.
CIN (Contrast-Induced Nephropathy): A causative subset of PC-AKI where the contrast is directly responsible. It excludes AKI from other concurrent insults (infection, nephrotoxic drugs, etc.).

(Brenner and Rector's The Kidney)

Definition

The most commonly used quantitative threshold is:

Serum creatinine rise ≥ 0.5 mg/dL (absolute), or ≥ 25% above baseline, within 48 hours of contrast - persisting 2-5 days.

Using AKIN/KDIGO criteria (as recommended by the ACR), PC-AKI is diagnosed if within 48 hours any of the following occur:

SCr rise ≥ 0.3 mg/dL (> 26.4 µmol/L)
SCr rise ≥ 50% (1.5x baseline)
Urine output ≤ 0.5 mL/kg/h for ≥ 6 hours

(Brenner and Rector's The Kidney)

Pathophysiology

Two main mechanisms operate together:

1. Renal Vasoconstriction / Medullary Ischemia

Biphasic hemodynamic response: brief initial vasodilation (seconds to minutes) followed by prolonged vasoconstriction.
Medullary hypoxia is worsened by contrast-induced increase in blood viscosity reducing vasa recta flow.
Osmotic diuresis increases sodium delivery to the thick ascending loop of Henle, raising oxygen consumption for reabsorption.

2. Direct Tubular Epithelial Toxicity

Reactive oxygen species (ROS) mediate proximal tubular injury (evidenced by low-molecular-weight proteinuria).
Activation of the aldose reductase-fructokinase pathway (stimulated by hyperosmolarity) in the proximal tubule.
Uricosuria may contribute to tubular injury.
High osmolality of contrast agents amplifies both mechanisms.

(Comprehensive Clinical Nephrology 7th Ed., Brenner & Rector's The Kidney)

Risk Factors

Category	Specific Factors
Renal	Pre-existing CKD (eGFR < 45 mL/min/1.73 m²), diabetic nephropathy
Cardiovascular	Congestive heart failure, low LVEDP, haemodynamic instability
Volume status	Dehydration/volume depletion (most significant modifiable factor)
Metabolic	Hyperuricemia, multiple myeloma (in dehydrated patients)
Demographic	Age > 75 years, hypertension
Drug-related	Concurrent NSAIDs, ACE inhibitors/ARBs, diuretics
Procedure-related	Intra-arterial > intravenous administration, high contrast dose, repeated/closely-timed studies, hyperosmolar contrast (HOCM)

Key point: IV contrast CT in patients with eGFR > 30 mL/min/1.73 m² carries very low CIN risk. Intra-arterial contrast (e.g., cardiac catheterisation) poses substantially higher risk due to larger required volumes and direct delivery to renal arteries.

(Comprehensive Clinical Nephrology 7th Ed.)

GFR Thresholds for Risk Stratification

eGFR (mL/min/1.73 m²)	Risk Level
> 45	Low risk for IV contrast
30-45	Moderate risk; preventive measures indicated
< 30	High risk; consider alternatives to contrast imaging
On dialysis	Contrast can be given; coordinate with dialysis schedule

ESUR (European Society of Urogenital Radiology): eGFR < 45 as the threshold for elevated risk.
Canadian Association of Radiologists: Risk starts at eGFR < 45, significantly increases at eGFR < 30.

(Brenner and Rector's The Kidney)

Prevention Strategies

1. Hydration / Volume Expansion (Most Important)

The single most evidence-based intervention. IV hydration improves renal blood flow, dilutes contrast in tubules, and suppresses RAAS activation.

Standard IV Protocol (inpatient):

Normal saline (0.9% NaCl) at 1-1.5 mL/kg/h for at least 6 hours before AND 6 hours after contrast administration.

Accelerated Protocol (emergency/pre-procedure):

3 mL/kg/h for 1 hour before, then 1 mL/kg/h for 6 hours after.

Sodium Bicarbonate Alternative:

Mix 154 mEq/L sodium bicarbonate in 1L D5W; give 3 mL/kg IV bolus over 1 hour pre-procedure, then 1 mL/kg/h for 6 hours post-procedure.
Rationale: urinary alkalinization reduces hydroxyl radical generation.
However, the PRESERVE trial (large multicenter RCT) found no benefit of bicarbonate over normal saline. The 2018 ACR guidelines do not recommend bicarbonate as preferred over saline.

Oral vs. IV hydration:

IV hydration is preferred (certainty of volume delivery); oral hydration is an acceptable alternative in outpatients with eGFR 30-45 when IV is impractical, but the evidence base is weaker.
In heart failure patients: withhold diuretics the day before and day of contrast; delay contrast until acute decompensation resolves.

(Brenner and Rector's The Kidney, Roberts and Hedges' Clinical Procedures in Emergency)

2. Choice of Contrast Agent

Use low-osmolar contrast media (LOCM) (e.g., iopamidol/Isovue, iohexol/Omnipaque) - standard of care; high-osmolar agents (HOCM) are no longer used intravascularly due to higher adverse effect profiles.
Iso-osmolar agents (e.g., iodixanol) have not shown clear superiority over LOCM in IV studies.
Minimize contrast volume - limit dose, especially in high-risk patients. Avoid contrast dose > 3-4 mL/kg or above the maximum contrast dose formula (5 mL × body weight (kg) / SCr).

(Brenner and Rector's The Kidney)

3. Timing Between Contrast Studies

Allow at least 24 hours between contrast-enhanced studies (time for normal-GFR kidneys to excrete contrast). In CKD, this interval should be longer.
Avoid repeat contrast-enhanced CT < 24 hours in high-risk patients.

4. Withhold Nephrotoxic and Haemodynamically-Active Drugs

Withhold NSAIDs, ACE inhibitors/ARBs, diuretics 24-48 hours before contrast in high-risk patients (controversial but commonly recommended).
Withhold metformin in eGFR < 60 mL/min before contrast, restart 48 hours after if kidney function is stable (to prevent lactic acidosis in the setting of AKI, not directly nephroprotective).
Discontinue any other concurrent nephrotoxins where clinically feasible.

5. N-Acetylcysteine (NAC)

Antioxidant thiol; mechanistic rationale: scavenges ROS, vasodilator.
Oral dose: 600 mg twice daily the day before and day of contrast.
IV dose (emergency): 150 mg/kg bolus over 30 min pre-procedure, then 50 mg/kg over 4 hours.
Evidence: Conflicting. Large RCTs (including the ACT trial) and meta-analyses show inconsistent results. The ACR does not classify NAC as proven. However, given low cost and minimal side-effect profile, some centres continue to use it alongside IV hydration.

(Brenner and Rector's The Kidney, Roberts and Hedges')

6. Other Pharmacological Agents (Emerging/Investigational)

Agent	Mechanism	Evidence Status
Statins (e.g., rosuvastatin)	Anti-inflammatory, antioxidant, pleiotropic	Promising in small RCTs; meta-analyses show benefit in PCI patients; not yet standard of care
Ascorbic acid	Antioxidant	Investigated; limited data
Fenoldopam	Dopamine-1 agonist, renal vasodilator	Early trials mixed; not recommended
Theophylline	Adenosine antagonist, renal vasodilator	Some benefit in small trials; not standard
SGLT2 inhibitors	Tubuloglomerular feedback modulation	Emerging data in PCI patients (meta-analysis PMID 41366914, 2025); potentially protective
Nicorandil	K-ATP channel opener, vasodilator	Meta-analysis (PMID 40340567, 2025) suggests potential benefit in coronary angiography patients

7. RenalGuard System

Matched urine output-guided hydration device that maintains high urine output (≥ 300 mL/h) during contrast procedures.
A 2025 systematic review (PMID 40099270) found it beneficial in CKD patients undergoing cardiac interventions.
Not widely available; reserved for high-risk catheterisation lab patients.

8. Consider Alternative Imaging

In patients at very high risk (eGFR < 30, solitary kidney, prior CIN):

Non-contrast CT for many indications
Ultrasound for vascular and renal assessment
MRI (note: gadolinium-based agents are contraindicated in eGFR < 30 due to nephrogenic systemic fibrosis risk with certain linear chelates)

Clinical Course & Management of Established CIN

Timeframe	Event
24 hours post-contrast	SCr begins to rise
96 hours (4 days)	SCr peaks
7-10 days	Returns to baseline in most patients

Management of established CIN is supportive - there is no specific antidote:

Continue aggressive IV hydration (unless volume overloaded).
Stop all nephrotoxins.
Monitor electrolytes, urine output, daily creatinine.
Manage complications of AKI - hyperkalaemia, metabolic acidosis, fluid overload, uraemia.
Renal replacement therapy (dialysis/haemofiltration) if: refractory hyperkalaemia, acidosis, fluid overload, or severe uraemia. Prophylactic dialysis to remove contrast is not recommended (contrast clears faster than dialysis can remove it, and dialysis itself carries risks).
Follow-up renal function at 1 week and 1 month to confirm recovery.

Patients who develop CIN have longer hospitalisation, higher short-term mortality, and higher rates of cardiac/neurologic events compared to matched controls - though some of this association may reflect confounding by underlying comorbidity severity rather than CIN causality.

(Brenner and Rector's The Kidney)

Summary Algorithm

Patient requiring contrast study
         |
         ├── Assess eGFR
         |
         ├── eGFR > 45 → Routine; no specific prevention needed
         |
         ├── eGFR 30-45 → IV hydration (NS 1 mL/kg/h x 6h pre + post)
         |                 Low-osmolar contrast; minimise volume
         |                 Withhold nephrotoxins
         |                 Consider NAC (600 mg PO BID x 2 days)
         |
         └── eGFR < 30 → Above PLUS consider alternative imaging
                          Discuss with nephrology
                          Inpatient monitoring post-procedure

Recent Evidence Update (2024-2026)

SGLT2 inhibitors pre-PCI (meta-analysis 2025, PMID 41366914): Pre-procedure SGLT2 inhibitor use in AMI patients undergoing PCI was associated with reduced CIN incidence. Mechanism likely involves tubuloglomerular feedback normalisation. Not yet in major guidelines but biologically plausible.
Nicorandil (meta-analysis 2025, PMID 40340567): Showed potential benefit in coronary angiography; larger trials needed.
Left Ventricular End-Diastolic Pressure (LVEDP) (systematic review 2026, PMID 38349134): Elevated LVEDP is independently associated with CIN risk in coronary angiography patients and may guide periprocedural hydration intensity.
The concept that IV contrast routinely causes clinically significant nephropathy in patients with preserved renal function has been substantially challenged by propensity-matched studies - risk may have been significantly overstated historically, particularly for IV (as opposed to intra-arterial) administration.

Sources: Brenner and Rector's The Kidney, 2-Vol Set | Comprehensive Clinical Nephrology, 7th Ed. | Roberts and Hedges' Clinical Procedures in Emergency Medicine | PubMed PMIDs: 40099270, 41366914, 38349134, 40340567

IMG_5978.jpeg

IMG_5977.jpeg

Abdomen pic with skin lesion

Reading File

Finding Sources

Reading File

Finding Sources

Loading Image

Finding Sources

Reading File

I now have enough information from both the image analysis and the textbook content. Let me compile a thorough clinical analysis.

Clinical Image Analysis - Abdominal Skin Lesions

Visual findings from both images:

Looking at the two photos of the abdomen, I can characterize the following:

Numerous small (1-3 mm), discrete, hyperpigmented brown macules/papules scattered diffusely across the abdominal skin
The lesions appear folliculocentric - each one appears to correspond to a hair follicle opening
Distribution is relatively uniform, non-confluent
Skin background appears otherwise intact, without erythema, scaling, or excoriation
The navel (umbilicus) is visible in the second image, confirming this is the anterior abdomen/periumbilical region
A single small red/erythematous lesion is also visible in image 2 (mid-lower abdomen)
No vesicles, bullae, or plaques visible

Differential Diagnosis

1. Keratosis Pilaris (KP) with Post-Inflammatory Hyperpigmentation - Most Likely

The most common cause of diffuse folliculocentric brown macules/papules on the trunk. Each follicular opening is plugged by a keratotic plug, and in darker skin tones, this leaves residual post-inflammatory hyperpigmentation (PIH). Classically affects the extensor arms, thighs, and buttocks but can involve the abdomen, particularly in individuals with fair/medium skin and a tendency to retain keratin.

Key features that fit: Follicular distribution, discrete uniform dots, no surrounding erythema in most lesions, no coalescence.

2. Comedones (Open/Closed) - Acne vulgaris / Truncal Acne

Open comedones (blackheads) on the trunk are a recognised pattern of truncal acne. The tiny dark dots at follicular openings could represent plugged infundibula with oxidized sebum (blackheads). The periumbilical and lower abdominal distribution is less classical (chest/back more typical) but not rare.

3. Milia

Tiny 1-2 mm white-to-pale yellow cysts arising from follicular infundibulae or eccrine ducts. However, classic milia are usually white/cream in colour, not brown-pigmented, so this is less likely as a sole diagnosis.

4. Darier Disease (Keratosis Follicularis) - Consider if Persistent

Darier disease presents with discrete, greasy, yellowish-brown keratotic papules in seborrheic distributions - including the trunk. The abdomen (especially intertriginous zones like the abdominal fold) can be involved. Features that would support this diagnosis: nail changes (longitudinal red-white bands, V-nicks), oral mucosal cobblestoning, family history, involvement of scalp/chest/back.

The Fitzpatrick textbook describes the lesions as: "discrete, greasy, yellowish-brown keratotic papules... predilection for seborrheic areas including central chest, upper back, scalp, neck, and skin creases (axillae, groins, perineum)" - Fitzpatrick's Dermatology

The distribution diagram from Dermatology 2-Volume Set (Elsevier) below shows the typical distribution for Darier, Hailey-Hailey, and Grover disease:

Distribution patterns for Darier, Hailey-Hailey, and Grover disease

5. Grover Disease (Transient Acantholytic Dermatosis)

Presents as pruritic, discrete, keratotic or crusted papules predominantly on the anterior chest and abdomen in middle-aged to older men, often triggered by heat, sweating, or systemic illness. The abdominal location fits Grover disease well (as seen in the distribution diagram above - purple zone covers the anterior chest and abdomen). However, Grover disease is typically pruritic and the papules are often crusted or vesicular at their peak.

6. Sebaceous Hyperplasia / Follicular Cysts

Enlarged sebaceous glands or small epidermoid cysts can appear as pale-yellow/white folliculocentric lesions, but these would typically be larger (2-5 mm) with a central pore.

7. Tinea Versicolor (Pityriasis Versicolor)

A fungal infection (Malassezia furfur) causing hypopigmented or hyperpigmented coalescing scaly macules on the trunk. In darker skin tones, lesions are often hyperpigmented. However, the macules in tinea versicolor are typically larger, more coalescent, and have fine scale - not strictly folliculocentric discrete dots.

Recommended Clinical Assessment

Step	Action
History	Duration, pruritus (Grover's is pruritic; KP/Darier's less so), family history (Darier's is autosomal dominant), acne history, prior similar lesions
Full skin exam	Check nails (Darier's), scalp, palms/soles, axillae, mucous membranes
Wood's lamp	Tinea versicolor fluoresces yellow-green
KOH scraping	If scale present - "spaghetti and meatballs" on KOH = Malassezia
Dermoscopy	Can distinguish follicular keratotic plugs (KP/Darier) from pigmented macules (PIH)
Skin biopsy	If Darier disease or Grover disease is suspected - shows acantholysis with corps ronds and corps grains (Darier) or similar changes (Grover)

Summary

The most likely diagnosis based on visual assessment is keratosis pilaris with post-inflammatory hyperpigmentation or truncal comedonal acne, given the uniform, discrete, folliculocentric brown dots without significant inflammation or coalescence. However, Darier disease and Grover disease should be actively excluded with a careful history, full skin exam, and dermoscopy/biopsy if the lesions are persistent or progressive.

Important disclaimer: This is a visual analysis for educational and differential-diagnostic purposes only. A formal dermatological examination, dermoscopy, and potentially skin biopsy are required for definitive diagnosis. Please consult a dermatologist.

Sources: Fitzpatrick's Dermatology, Dermatology 2-Volume Set 5th Ed. (Elsevier), Andrews' Diseases of the Skin

Also complaining of bl sole burning and numb sensations

Finding Sources

Reading File

Finding Sources

I now have sufficient content. Here is the integrated clinical analysis combining the skin lesions with the new symptom of bilateral sole burning and numbness.

Integrating the Full Clinical Picture

Symptoms so far:

Multiple small folliculocentric brown macules/papules on the abdomen
Bilateral sole burning and numbness (new symptom)

This combination significantly narrows the differential. The key question is: what single unifying diagnosis explains both skin lesions on the trunk AND a length-dependent sensory neuropathy affecting the soles?

Top Unifying Diagnoses

1. Diabetes Mellitus - Most Likely Unifying Diagnosis

This is the single most important diagnosis to consider.

Skin connection:

Diabetic skin lesions include multiple findings visible on the abdomen: diabetic dermopathy (brown macules), follicular hyperkeratosis, and acanthosis nigricans in skin folds. The scattered brown follicular macules fit diabetic dermopathy well.
Diabetes is also directly associated with Darier-like follicular keratosis patterns in some patients.

Neuropathy connection:

Diabetic peripheral neuropathy (DPN) is the most common cause of bilateral burning/numb feet worldwide.
It follows a classic length-dependent, stocking-glove pattern - starting in the soles and ascending.
Characterised by small-fiber involvement initially: burning, heat sensation, dysesthesias, followed by numbness as large fibers are progressively lost.
Adams & Victor's Principles of Neurology lists diabetes as the leading identifiable cause of painful sensory neuropathy.

Key investigations to order:

Fasting blood glucose, HbA1c, OGTT
Urine microalbumin

2. Nutritional / Vitamin Deficiency Neuropathy

Several vitamin deficiencies cause both skin and nerve changes:

Deficiency	Skin Findings	Neuropathy
B3 (Niacin/Pellagra)	Photosensitive dermatitis, hyperpigmented skin lesions	Small-fiber neuropathy - classic "burning feet"; dysesthesias and paresthesias
B12 (Cobalamin)	Hyperpigmentation (especially in darker skin tones)	Subacute combined degeneration + painful sensory neuropathy
B1 (Thiamine)	Non-specific	Classic burning feet / beri-beri neuropathy
B5 (Pantothenic acid)	Non-specific	Small-fiber neuropathy with "burning feet" - direct quote from Goldman-Cecil Medicine

Goldman-Cecil Medicine states specifically: "The neurologic syndrome associated with B5 deficiency is presumed to be a small-fiber neuropathy with dysesthesias and paresthesias that result in 'burning feet.'"

Key investigations:

Serum B12, folate, B1, B3 (niacin) levels
Full blood count (macrocytic anaemia in B12 deficiency)
Dietary history - malnutrition, alcohol use, malabsorption

3. Fabry Disease - Important Rare Diagnosis Not to Miss

An X-linked lysosomal storage disorder (alpha-galactosidase A deficiency) that classically presents with:

Angiokeratomas - small dark red-brown papules on the trunk/abdomen (which can be mistaken for simple pigmented macules, especially in early disease or darker skin)
Burning neuropathic pain in extremities - typically described as burning/tingling in the hands and feet; this is often the first symptom in young patients
Corneal verticillata, renal disease, cardiomyopathy develop later

Adams & Victor's Principles of Neurology explicitly lists Fabry disease in the table of causes of painful sensory neuropathy (burning feet).

Key investigations:

Alpha-galactosidase A enzyme activity (leukocytes) - males
GLA gene mutation testing - females and equivocal cases
Urine sediment for lipid-laden cells

4. Darier Disease + Incidental Small Fiber Neuropathy

As noted previously, Darier disease (ATP2A2 mutation) has been associated with neuropsychiatric comorbidities and there are case reports of associated autonomic and small-fiber neuropathy. However, this would be a coincidence of two separate diagnoses rather than a true unifying one.

5. Pellagra (Niacin/B3 Deficiency)

Pellagra classically produces the "4 Ds":

Dermatitis - photosensitive, hyperpigmented skin (can appear as brownish macular pigmentation)
Diarrhea
Dementia/neuropsychiatric symptoms
Death (if untreated)

The hyperpigmented truncal macules + burning neuropathy fits pellagra well, especially in a patient with poor nutrition, alcohol use, or malabsorption (e.g., coeliac disease, Crohn's, dialysis).

6. HIV/AIDS-Related

HIV is listed among causes of painful sensory neuropathy (burning feet). HIV dermatitis can produce follicular papules and pigmented macules on the trunk. This should be in the differential in appropriate clinical context.

Recommended Workup - Prioritised

Tier 1 (Do Immediately)

Test	Rationale
HbA1c + fasting glucose	Diabetes - most common unifying cause
Serum B12, folate	B12 neuropathy + hyperpigmentation
Full blood count	Macrocytic anaemia (B12/folate), anaemia
Serum B1, B3, B5 levels	Nutritional neuropathy
Renal function, eGFR	Uraemic neuropathy
LFTs + GGT	Alcohol-related, hepatic

Tier 2 (Based on Tier 1 Results / Clinical Suspicion)

Test	Rationale
Alpha-galactosidase A	Fabry disease
HIV serology	HIV neuropathy
Nerve conduction studies (NCS) + EMG	Characterise neuropathy type (axonal vs demyelinating; length-dependent)
Skin biopsy (punch biopsy) for intraepidermal nerve fiber density (IENFD)	Diagnose small fiber neuropathy specifically
ANA, ANCA, anti-Ro/La, anti-Sm	Connective tissue disease (Sjögren's, SLE)
Serum protein electrophoresis (SPEP)	Paraproteinaemia/amyloidosis
Thyroid function (TSH, free T4)	Hypothyroid neuropathy

Tier 3 (Specialist Referral)

Dermatology - Skin biopsy of the abdominal lesions
Neurology - Formal neuropathy workup
Ophthalmology - Corneal slit-lamp exam if Fabry disease suspected (corneal verticillata)

Summary: Clinical Synthesis

Bilateral sole burning/numbness
        +
Truncal folliculocentric brown macules
        ↓
THINK SYSTEMICALLY:
  1. Diabetes mellitus (most common)
  2. Nutritional deficiency (B1/B3/B5/B12)
  3. Fabry disease (rare but treatable - don't miss)
  4. HIV
  5. Connective tissue disease

Start with: HbA1c, B12, FBC, RFT, LFTs, TSH
Refer: Dermatology + Neurology

Important note: Bilateral burning and numbness of the soles represents a small-fiber neuropathy pattern until proven otherwise. The most important immediate step is to exclude diabetes (HbA1c) and nutritional deficiencies (B12, B1, B3) - both of which are common, treatable, and directly explain the skin and neurological findings together.

Sources: Adams and Victor's Principles of Neurology 12th Ed. | Goldman-Cecil Medicine | Bradley and Daroff's Neurology in Clinical Practice | Harrison's Principles of Internal Medicine 22E

Her reports

Reading File

Running Command

python3 -c " import pdfplumber with pdfplumber.open('/home/daytona/workspace/attachments/a7cf4574-3f46-43d5-81d9-f5df06bcf83c/60502200662.pdf') as pdf: print(f'Pages: {len(pdf.pages)}') for i, page in enumerate(pdf.pages): print(f'--- PAGE {i+1} ---') text = page.extract_text() if text: print(text) tables = page.extract_tables() for j, table in enumerate(tables): print(f'[Table {j+1}]') for row in table: print(row) "

Finding Sources

I have all the data I need. Here is the complete, integrated clinical report analysis.

Lab Report Analysis - Ramilaben Valera, F/57 (Dated: 24-May-2026)

Complete Results Summary

Test	Result	Reference	Status
Haemoglobin	12.0 g/dL	12.0-15.0	Low-normal (borderline)
PCV	35.96%	36.0-46.0	LOW ↓
MCV	93.4 fL	83-101	Normal
WBC	8130 /µL	4000-10000	Normal
Platelets	312,000 /µL	150k-410k	Normal
ESR	20 mm/hr	3-30	Normal
Fasting Glucose	97.37 mg/dL	70-100	Normal
HbA1c	5.78%	<5.7 Normal / 5.7-6.4 Prediabetes	PREDIABETES ⚠️
Urea	27.83 mg/dL	18-55	Normal
Creatinine	0.57 mg/dL	0.5-1.1	Normal
Uric acid	4.87 mg/dL	2.3-6.1	Normal
Sodium/K/Cl	All normal		Normal
LFT (ALT/AST/ALP/GGT)	All normal		Normal
Total Cholesterol	220.5 mg/dL	<200	HIGH ↑
HDL Cholesterol	36.7 mg/dL	40-60	LOW ↓
LDL Cholesterol	144.49 mg/dL	<100	HIGH ↑
Triglycerides	196.53 mg/dL	40-200	High-normal (borderline)
VLDL	39.31 mg/dL	10-40	Borderline high
Chol/HDL ratio	6.01	<4.1	HIGH ↑ (atherogenic)
Vitamin B12	351.2 pg/mL	187-883	Normal
Vitamin D (25-OH)	25.3 ng/mL	30-100 Normal; 20-30 Insufficiency	INSUFFICIENT ↓
Calcium	9.07 mg/dL	8.4-10.2	Normal
Urine	All negative		Normal
ANA (IIF)	PENDING		Result awaited

Key Abnormalities - Clinical Interpretation

1. HbA1c 5.78% - PREDIABETES

This is the single most clinically important finding in the context of her symptoms.

HbA1c 5.78% places her firmly in the prediabetes range (5.7-6.4%).
Estimated average glucose over the past 3 months: 119 mg/dL.
The fasting glucose of 97 mg/dL is normal (not yet impaired fasting glucose), but HbA1c tells a different story - indicating higher average glycaemia throughout the day.

Critical link to her symptoms:

Prediabetic small-fiber neuropathy is now a well-recognised entity. Bilateral burning and numbness of the soles can begin in the prediabetic stage, before frank diabetes develops. The small sensory C-fibres and Aδ-fibres in the feet are among the first to be damaged by chronic mild hyperglycaemia. This explains both the burning sensation (positive sensory symptoms = small fiber C-fiber damage) and the numbness (loss of sensation = progressive fiber loss).

Action required:

Lifestyle intervention NOW - dietary modification, weight management, regular exercise can reverse prediabetes and halt neuropathy progression
Repeat HbA1c in 3-6 months
Oral glucose tolerance test (OGTT) to better characterise glucose metabolism
Refer to diabetologist/endocrinologist

2. Dyslipidaemia - Atherogenic Pattern

This patient has a significantly abnormal lipid profile fitting the pattern of metabolic syndrome dyslipidaemia:

Finding	Value	Significance
Total cholesterol 220.5	HIGH	+20.5 above upper limit
LDL 144.49 mg/dL	HIGH	44 points above the <100 target
HDL 36.7 mg/dL	LOW	Below the protective threshold
Chol/HDL ratio 6.01	HIGH	>4.1 = elevated cardiovascular risk
TG 196.53	High-normal	Near the 200 cutoff

The Chol/HDL ratio of 6.01 (normal <4.1) is a strong predictor of atherosclerotic cardiovascular disease (ASCVD) risk. Combined with prediabetes, this puts her in a higher cardiovascular risk category.

Dyslipidaemia + prediabetes together = metabolic syndrome - check waist circumference, blood pressure.

Also relevant to skin: Hypercholesterolaemia can produce xanthelasma (periorbital) and xanthomas (tendon/skin deposits) in severe or familial cases. In this patient, however, the skin lesions appear folliculocentric rather than xanthomatous.

Action required:

Statin therapy discussion (given LDL >140 + prediabetes + atherogenic ratio)
Dietary counselling: reduce saturated fats, refined carbohydrates, increase omega-3 rich foods
Lifestyle modification: exercise significantly raises HDL
Repeat fasting lipid profile in 6-8 weeks after lifestyle changes
Calculate 10-year ASCVD risk (Framingham / PCE score)

3. Vitamin D 25.3 ng/mL - INSUFFICIENCY

Level: 25.3 ng/mL (Normal ≥30; Insufficiency = 20-<30; Deficiency <20)
She is in the insufficiency zone.

Link to symptoms:

Vitamin D insufficiency is increasingly associated with musculoskeletal pain, fatigue, and neuropathic-type symptoms including paraesthesias and burning sensations in the feet - though this is likely a contributing/aggravating factor rather than the primary cause in her case.
Low Vitamin D also potentiates insulin resistance and impairs beta-cell function, making her prediabetes harder to reverse.
Low Vitamin D can worsen dyslipidaemia by upregulating HMG-CoA reductase.

Action required:

Cholecalciferol (Vitamin D3) supplementation: 60,000 IU weekly for 8-12 weeks (loading dose), then 1000-2000 IU/day maintenance
Recheck 25-OH Vitamin D after 3 months
Encourage sun exposure (20-30 min/day)
Also check PTH to assess secondary hyperparathyroidism from Vit D insufficiency

4. PCV 35.96% - Borderline Low (Mild Anaemia)

Haemoglobin is at the lower limit of normal (12.0 g/dL = exactly the lower reference limit for females).
PCV 35.96% is just below normal (36-46%).
MCV is normal (93.4 fL) - normocytic - so this is NOT B12 deficiency anaemia (which is macrocytic).
B12 level is normal at 351 pg/mL - B12 neuropathy is excluded.
Possible cause: Iron deficiency without anaemia, or mild anaemia of chronic disease. Ferritin, serum iron, TIBC not done.

Action required:

Check serum ferritin and iron studies to exclude iron deficiency
Menstrual history (postmenopausal at 57?)
Repeat CBC in 3 months

5. ANA (IIF) - PENDING

This test was ordered and is still awaited. ANA was in our differential (connective tissue disease causing neuropathy - Sjögren's syndrome being particularly important). This result must be followed up - Sjögren's syndrome can cause:

Small fiber neuropathy with burning feet
Dry skin with follicular changes
Normal B12, normal glucose

Integrated Clinical Picture

Putting it all together:

57-year-old woman
├── SKIN: Multiple small folliculocentric brown macules, abdomen
├── NEURO: Bilateral sole burning + numbness
└── LABS:
    ├── HbA1c 5.78% → PREDIABETES ← MOST LIKELY CAUSE OF NEUROPATHY
    ├── Dyslipidaemia (LDL↑, HDL↓, Chol/HDL ratio↑) → METABOLIC SYNDROME
    ├── Vitamin D insufficiency → CONTRIBUTING FACTOR
    ├── Borderline anaemia (normocytic) → Fe studies needed
    ├── B12 normal → B12 neuropathy EXCLUDED
    └── ANA → PENDING (rule out Sjögren's/SLE)

Most likely unified diagnosis: Metabolic syndrome comprising:

Prediabetes (HbA1c 5.78%)
Atherogenic dyslipidaemia (high LDL, low HDL, high TG)
Vitamin D insufficiency

The skin lesions likely represent follicular keratosis/prediabetic dermopathy associated with insulin resistance. The bilateral burning feet are most likely a prediabetic small-fiber neuropathy - a real and increasingly recognised complication that starts before frank diabetes.

Priority Management Plan

Priority	Action
Immediate	Lifestyle modification: diet, exercise, weight reduction - can reverse prediabetes
Immediate	Start Vitamin D3 supplementation (60,000 IU/week x 8 weeks, then maintenance)
Soon	Statin therapy discussion with physician - given LDL 144 + prediabetes
Soon	OGTT (75g oral glucose tolerance test) - better characterise glucose status
Soon	Serum ferritin + iron studies (for borderline anaemia)
Soon	Blood pressure measurement, waist circumference (complete metabolic syndrome assessment)
Follow up	ANA result - if positive, rheumatology referral for Sjögren's workup
Follow up	Repeat HbA1c in 3-6 months after lifestyle changes
Refer	Neurology or Diabetologist for formal neuropathy assessment (NCS/EMG, IENFD skin biopsy)
Refer	Dermatology for skin biopsy of abdominal lesions

Note for the physician: The absence of frank diabetes (fasting glucose is normal at 97 mg/dL) does not exclude prediabetic neuropathy. HbA1c-based prediabetes with small-fiber neuropathy is well-documented in the literature. Early aggressive lifestyle intervention in this window can prevent progression to diabetes and potentially reverse the neuropathy.

Utkarsh small finance bank rating and review compared to other small finance bank and is it safe

Searching the Web

Utkarsh Small Finance Bank credit rating financial health 2025 2026

Searching the Web

small finance bank comparison safety rating India 2025 NPA CRAR

Searching the Web

Utkarsh SFB vs AU Jana Equitas ESAF small finance bank comparison NPA CRAR deposits 2025 2026

Reading Web Page

https://www.careratings.com/upload/CompanyFiles/PR/202601120…

Searching the Web

DICGC deposit insurance small finance bank safety India 5 lakh protection 2025

Reading Web Page

https://groww.in/blog/top-small-finance-bank-stocks-in-india

I now have comprehensive data. Here is the complete analysis.

Utkarsh Small Finance Bank - Rating, Review & Safety Analysis

Quick Profile

Parameter	Details
Full Name	Utkarsh Small Finance Bank Limited (USFBL)
Headquarters	Varanasi, Uttar Pradesh
Founded	2009 (as MFI); SFB licence from RBI in 2017
Listed	BSE & NSE (IPO: July 2023)
Market Cap	~₹2,731 crore (Dec 2025)
Deposits	₹21,087 crore (Dec 2025)
Loan Book	₹18,306 crore (Dec 2025)
Branches	~900+ across UP, Bihar, and other states
Focus	Microfinance / JLG loans + retail banking

Credit Ratings (Most Recent - January 2026)

Rating Agency	Instrument	Rating	Outlook	Action
CARE Ratings	Tier-II Bonds (₹200 cr)	CARE A	Negative	Downgraded from CARE A+; Outlook revised from Stable to Negative
ICRA	Subordinated Debt (₹400 cr)	[ICRA]A (Negative)	Negative	Downgraded from [ICRA]A+ (Negative)
ICRA	Certificates of Deposit (₹1,000 cr)	[ICRA]A1+	-	Reaffirmed

What this means:

'A' rating = good credit quality, but not the highest tier
Negative outlook = rating may be downgraded further if things don't improve
Both major agencies downgraded the bank's long-term rating in August 2025
Short-term liquidity (A1+) is still strong - the bank can pay its short-term obligations

Key Financial Metrics (Latest Available - Dec 2025 / H1FY26)

Metric	Utkarsh SFB	Ideal Range
CRAR (Capital Adequacy)	20.1% (Dec 2025)	RBI minimum: 15%
Gross NPA ratio	~12.42% (Sep 2025)	<5% preferred
Net NPA ratio	Elevated	<2% preferred
NNPA/Net Worth	41.10% (Sep 2025)	<20% preferred
Provision Coverage Ratio	~59-69% (microfinance book)	>70% preferred
LCR (Liquidity Coverage)	241%	Minimum: 100%
CASA ratio	~20% (Jun 2025)	25-30%+ preferred
Net Interest Margin	~5.4% (9MFY26)	Good for SFB
Net Loss (H1FY26)	₹588 crore loss	-
Net Loss (Q3FY26)	₹375 crore loss	-

Red flags clearly visible:

GNPA of 12.42% is very high - nearly 1 in 8 loans is non-performing
The bank reported a net loss of ₹588 crore in H1FY26 vs profit of ₹498 crore in FY24
Stress is concentrated in its microfinance/JLG book (44% of loans), which was affected by the MFIN Guardrail 2.0 regulations from April 2025

Green flags:

Capital adequacy at 20.1% - well above the 15% minimum; raised ₹950 crore via rights issue (Nov 2025)
Liquidity coverage ratio at 241% - very strong; no liquidity stress
Deposit franchise stable - deposits reached ₹21,487 crore; 74% retail deposits
Fresh NPA slippages declining in Q3FY26 - management says stress has peaked
Pivoting from microfinance (62% → 44%) toward secured lending (housing, MSME, CV loans)

Comparison with Other Small Finance Banks

SFB	Market Cap	Deposits	Gross NPA	CRAR	Credit Rating	Status
AU SFB	₹73,173 cr	₹1,38,420 cr	~2.3%	~20%+	AA- / High	Best in class
Ujjivan SFB	₹10,501 cr	₹42,223 cr	Moderate	Adequate	A+ range	Recovering well
Equitas SFB	₹6,817 cr	₹43,668 cr	~2.9%	Adequate	A+ range	Good
Jana SFB	₹4,395 cr	₹33,733 cr	Elevated	Adequate	A range	Watch
Utkarsh SFB	₹2,732 cr	₹21,087 cr	~12.4%	20.1%	A (Negative)	Under stress
ESAF SFB	Small	₹24,006 cr	Elevated	Adequate	A range	Under stress
Capital SFB	Small	~₹8,000 cr	Low	Good	-	Niche/stable

Summary ranking for depositor safety (best to most risky):

🟢 AU SFB - Best asset quality, largest, AA- rated
🟢 Equitas SFB - Good asset quality, Chennai-based
🟢 Ujjivan SFB - Recovering well, wide network
🟡 Jana SFB - Moderate stress, watch carefully
🟠 Utkarsh SFB - High NPA, under stress but well-capitalised
🟠 ESAF SFB - High microfinance exposure, similar stress profile

Is Utkarsh SFB Safe for Deposits?

For deposits up to ₹5 lakh - YES, Safe

All scheduled commercial banks (including all SFBs) are covered under DICGC (Deposit Insurance and Credit Guarantee Corporation), a wholly owned subsidiary of RBI. This means:

Every depositor is insured up to ₹5,00,000 (principal + interest combined) per bank, regardless of what happens to the bank.

Even if Utkarsh SFB were to fail (which is not being suggested), deposits up to ₹5 lakh are fully protected.

For deposits above ₹5 lakh - Exercise Caution

Given the current situation:

GNPA of 12.42% is a significant concern - among the highest in the SFB sector
The bank is posting net losses (₹375 crore in Q3FY26 alone)
Both CARE and ICRA have Negative outlooks, meaning further downgrades are possible
The microfinance sector stress is industry-wide, but Utkarsh has higher exposure than peers

However, there are important mitigating factors:

Capital adequacy (20.1%) is robust - the bank has a substantial buffer to absorb losses
Liquidity is strong (LCR 241%) - no risk of a liquidity crisis
₹950 crore rights issue completed in November 2025 - shareholders have backed the bank
RBI-regulated and monitored - SFBs face stricter oversight than cooperative banks
Fresh NPAs declining - management reports Q3FY26 stress is peaking out

Practical Guidance

Situation	Recommendation
FD under ₹5 lakh	Safe (DICGC insured). Utkarsh offers competitive FD rates (typically 7.5-9%+). Can consider.
FD above ₹5 lakh	Consider spreading across multiple banks to stay within ₹5L per bank, or choose a higher-rated bank (AU SFB, Equitas) for the excess amount
Large corporate/institutional deposits	Not recommended currently given Negative outlook
Long-term FD (3-5 years)	Be cautious - wait for Q4FY26 results to see if NPA trend reverses before committing large sums
Savings account	Fine for regular use

Bottom Line

Utkarsh SFB is going through a stress period driven by the sector-wide microfinance crisis of 2024-2026. It is not in immediate danger of failing - capital and liquidity are strong, and it has RBI backing. But it is not the safest SFB right now either.

For small depositors (≤₹5 lakh): It is fully safe due to DICGC insurance, and its FD rates are attractive.
For larger deposits: AU SFB or Equitas/Ujjivan are safer choices at this time.
The bank's recovery depends on whether its microfinance NPA stabilises in Q4FY26 and FY27 - watch for the next quarterly results.

Sources: CARE Ratings Jan 2026 | ICRA Aug 2025 | Utkarsh Q3FY26 Investor Presentation | DICGC (RBI subsidiary)

What about sarvoday and Shivalik

Searching the Web

Suryoday Small Finance Bank rating NPA CRAR financial health 2025 2026 ICRA CARE

Searching the Web

Shivalik Small Finance Bank rating NPA CRAR financial performance 2025 2026

Reading Web Page

https://infomericstorage.blob.core.windows.net/uploads/pr_Sh…

All data in. Here is the full detailed analysis of both banks.

Suryoday & Shivalik Small Finance Banks - Full Analysis

SURYODAY Small Finance Bank

Quick Profile

Parameter	Details
HQ	Navi Mumbai, Maharashtra
Started as SFB	2017
Listed	BSE & NSE (Scrip: SURYODAY)
Focus	Microfinance (Individual Finance / JLG), MSME, home loans
Geographic Strength	Maharashtra, Tamil Nadu, Odisha
Customers	~38 lakh clients
Deposits	~₹13,000 crore (Dec 2025)
Advances	~₹12,000 crore (Dec 2025)
Total Assets	₹17,039 crore

Credit Ratings (March 2026 - Most Recent)

Agency	Instrument	Rating	Outlook	Action
ICRA	Subordinated Debt (₹100 cr)	[ICRA]A (Stable)	Stable	Reaffirmed
ICRA	Certificates of Deposit (₹130 cr)	[ICRA]A1+	-	Reaffirmed

Key difference from Utkarsh: Suryoday's outlook is Stable, not Negative. This means ICRA does not expect further downgrades in the near term.

Key Financial Metrics

Metric	FY2024	FY2025	9M FY2026 (Dec 25)
CRAR	28.4%	25.8%	21.9%
Tier I (CET1)	26.5%	24.5%	21.0%
Gross NPA	2.9%	7.2%	6.7% ↓ improving
Net NPA	0.9%	4.6%	4.3%
PAT (Profit)	₹216 cr	₹115 cr	₹102 cr (9 months)
ROA	1.9%	0.8%	0.8%
CASA ratio	~20%	21%	21%
Net profit Q3FY26	-	-	₹36.56 cr ↑ (up 9.79% YoY)

Strengths

Still profitable - unlike Utkarsh which posted huge losses, Suryoday is making a profit, albeit smaller than before (₹36.56 cr in Q3FY26, up 9.79% YoY)
GNPA is improving - peaked at 7.2% in March 2025, now declining to 6.7% in Dec 2025
CGFMU guarantee cover - a standout feature: 98% of its microfinance portfolio is covered by the Credit Guarantee Fund for Micro Units (CGFMU). This means the government backstops most microfinance losses - a significant risk mitigant not shared by all SFBs
CRAR of 21.9% - well above 15% minimum; Tier I at 21%, very strong
Stable outlook on ICRA rating - no imminent downgrade risk
Strong deposit growth - deposits up 32.5% YoY to ~₹13,000 crore
Slippages reducing sharply - ₹206 cr → ₹155 cr quarter-on-quarter in Q3FY26
X-bucket collection efficiency at 99.5% (Dec 2025) - nearly fully collecting on current loans

Weaknesses

GNPA of 6.7% is still elevated (though improving)
CASA ratio of 21% is low - means higher cost of funds
Profitability still under pressure vs pre-stress levels (ROA at 0.8% vs 1.9% in FY24)
Concentrated in Maharashtra/Tamil Nadu/Odisha - geographic concentration risk

FD Rates (Indicative, April 2026)

Regular: ~8.25% p.a. (1-year)
Senior Citizens: ~8.75% p.a.

Suryoday Safety Assessment

Factor	Status
DICGC Insurance (≤₹5L)	✅ Fully protected
Rating	A (Stable) - Good
Capital Buffer	✅ Very strong (CRAR 21.9%)
Profitability	⚠️ Reduced but still positive
NPA trend	✅ Improving (peaked and declining)
Unique protection	✅ 98% microfinance covered by CGFMU guarantee

Overall: Moderate-High safety. Suryoday is in a significantly better position than Utkarsh right now - it's still profitable, NPA is declining, and its Stable outlook is reassuring. The CGFMU guarantee on microfinance loans is a real differentiator.

SHIVALIK Small Finance Bank

Quick Profile

Parameter	Details
HQ	Saharanpur, Uttar Pradesh
Origin	Converted from Shivalik Mercantile Co-operative Bank (est. 1997)
Started as SFB	April 26, 2021 (newest among major SFBs)
Listed	Not publicly listed (unlisted bank)
Focus	MSME, agriculture, retail loans; originally Punjab/Haryana/UP focused
Branches	215 branches across 105 districts, 7 states
Deposits	₹4,218 crore (Dec 2025)
Advances	₹4,007 crore (Dec 2025)
Size	Smallest among notable SFBs

Credit Rating (February 2026 - Most Recent)

Agency	Instrument	Rating	Outlook	Action
Infomerics	Tier-II Bonds (₹50 cr)	IVR A / Stable	Stable	Reaffirmed; Outlook revised from Positive → Stable

Note: Shivalik is rated by Infomerics (smaller agency), not ICRA/CARE/CRISIL. This is because of its smaller size. The outlook was downgraded from Positive to Stable in Feb 2026 - a mild negative signal.

Key Financial Metrics

Metric	FY2024	FY2025	9M FY2026 (Dec 25)
CRAR	20.19%	20.95%	20.80%
Gross NPA	2.01%	2.70%	2.80%
Net NPA	0.84%	1.51%	2.10%
PAT (Profit)	₹2.40 cr	₹0.95 cr	₹4.50 cr (9 months)
NIM	5.95%	5.46%	4.80% ↓
ROA	0.09%	0.03%	0.10%
CASA	27.98%	22.42%	20.35% ↓ declining
LCR	-	-	171.42%
Total Business	₹4,530 cr	₹6,131 cr	₹8,225 cr

Strengths

GNPA of only 2.80% - best asset quality in this comparison; did NOT have heavy microfinance exposure, so largely escaped the 2024-26 MFI crisis
CRAR of 20.80% - solid capital adequacy
Profitable (₹4.50 cr PAT in 9M FY26 vs ₹0.95 cr full FY25) - recovering profitability
LCR 171.42% - adequate liquidity
Strong parentage - converted from a cooperative bank with 25+ years history; strong local trust base in UP/Punjab/Haryana
SMBC Asia Rising Fund as institutional investor - adds credibility
Rapidly growing - total business grew from ₹4,530 cr (FY24) to ₹8,225 cr (9M FY26) - nearly doubling in 2 years
Unaffected by MFI crisis - because its loan book is predominantly MSME, agri, and secured retail, not JLG microfinance

Weaknesses

Very small bank - ₹4,218 cr deposits vs ₹21,000+ cr for Utkarsh; limited scale
Extremely low profitability - ROA of 0.10% is among the weakest; profits are tiny in absolute terms
Relies on equity infusions to maintain capital - internal generation is insufficient; SMBC Asia fund keeps injecting capital (₹96 cr in FY25, ₹102 cr in 9M FY26)
CASA declining - from 27.98% (FY24) to 20.35% (Dec 2025) - costlier deposits
NIM compressing - from 5.95% to 4.80% - margin pressure
Geographic concentration - still heavily Punjab/UP dependent (though expanding)
Unlisted - no market price discovery; less transparency
Smaller rating agency (Infomerics) - less widely tracked

Shivalik Safety Assessment

Factor	Status
DICGC Insurance (≤₹5L)	✅ Fully protected
Rating	A/Stable (Infomerics) - Adequate
Capital Buffer	✅ Good (CRAR 20.80%)
Asset Quality	✅ Best among stressed-SFB peers (GNPA 2.8%)
Profitability	⚠️ Very thin but positive
Size/Scale	⚠️ Small; limited systemic importance

Overall: Reasonable safety for small deposits. Shivalik avoided the microfinance meltdown and its NPA is genuinely low. But its tiny profit margins and dependence on external equity raises are structural concerns. It is a niche, regional bank suited for depositors in its home territory.

Full Comparison Table (All Major SFBs)

SFB	GNPA	CRAR	Rating	Outlook	Profit	Size	Depositor Safety
AU SFB	~2.3%	~20%+	AA-/A+	Stable	Strong	₹1.38L cr deposits	🟢 Excellent
Ujjivan SFB	Moderate	Adequate	A+	Stable	Good	₹42,223 cr	🟢 Very Good
Equitas SFB	~2.9%	Adequate	A+	Stable	Good	₹43,668 cr	🟢 Very Good
Shivalik SFB	2.80%	20.80%	A/Stable	Stable	Thin	₹4,218 cr	🟢 Good (small bank)
Suryoday SFB	6.7% ↓	21.9%	A/Stable	Stable	Positive	₹13,000 cr	🟡 Moderate-Good
Jana SFB	Elevated	Adequate	A range	Watch	Pressure	₹33,733 cr	🟡 Moderate
Utkarsh SFB	12.42%	20.1%	A/Negative	Negative	Loss-making	₹21,087 cr	🟠 Caution (>₹5L)
ESAF SFB	High	Adequate	A range	Negative	Pressure	₹24,006 cr	🟠 Caution

Practical Recommendation

Your Situation	Best Choice
Safety-first depositor, ≤₹5L	Any SFB (all DICGC-insured); go for best FD rate
Safety-first, >₹5L	AU SFB > Equitas/Ujjivan > Suryoday > Shivalik > Utkarsh
Good rates + decent safety	Suryoday (8.25%) or Shivalik (competitive rates, low NPA)
North/UP-based, local trust	Shivalik - strong co-op legacy, low NPA
Recovery play (risk-tolerant)	Utkarsh or ESAF - high stress now but may recover

Bottom line: Suryoday is better positioned than Utkarsh right now - still profitable, NPA declining, CGFMU guarantee is unique protection. Shivalik is the hidden gem for low NPA quality, but is very small. For deposits above ₹5 lakh, Suryoday or AU/Equitas are preferable over Utkarsh at this stage.

Sources: ICRA - Suryoday Mar 2026 | Infomerics - Shivalik Feb 2026 | Suryoday Q3FY26 Investor Presentation

This is a shared conversation. Sign in to Orris to start your own chat.